Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Program of ONO-7702 + ONO-7703 in BRAF V600-mutant Thyroid Cancer
jRCT2011230032Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of encorafenib and binimetinib in thyroid cancer, sponsored by Ono Pharmaceutical. Primary endpoints: Safety and Efficacy. Started Jan 2024; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on jRCT2011230032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230032.